Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In the ATTAIN-1 Phase 3 trial, the most frequently reported adverse events with orforglipron 36 mg versus placebo were nausea (33.7% vs 10.4%), constipation (25.4% vs 9.3%), diarrhea (23.1% vs 9.6%), and vomiting (24.0% vs 4.0%)
About half of Contrave trial participants lost at least 5% of their body weight
What Do Stool (Poop) Color Changes and Warning Signs Mean
GLP-1RA Reward Behaviour Systematic Review (PubMed, 2024) GLP-1 Receptor Signalling in Reward Circuitry, Dopamine, and Addiction Research A systematic review of GLP-1 receptor agonist effects on reward behaviour published on PubMed following PRISMA guidelines across OVID, PubMed, Scopus, and Google Scholar evaluated the evidence for GLP-1Rs role in reward dysfunction across obesity, type 2 diabetes, and psychiatric conditions
US$ 25.30
US$ 24.25
US$ 22.33
US$ 25.45
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
US$ 20.46
US$ 24.62
:max_bytes(150000):strip_icc()/Health-GettyImages-1675158771-70640c9fdf1b41078975cfc3fd538a6b.jpg)
US$ 24.10
US$ 26.61
